Decoy Therapeutics (DCOY)

The company operates as a single business focused on therapeutic research and development. Its pipeline is built around peptide conjugates, a class of medicines that can be engineered to improve targeting, potency, or delivery characteristics. This approach is particularly relevant in areas where traditional small molecules, antibodies, or vaccines may not fully address the biology of a disease or may be limited by manufacturing complexity.

Decoy’s disclosed programs include candidates aimed at pan-coronavirus applications and a “Tripledemic” program, reflecting an interest in respiratory infectious diseases and viral threats. As a pre-clinical company, its assets remain at an early stage and must still pass through laboratory validation, regulatory review, and clinical testing before any commercial use is possible.

For investors, Decoy represents an early-stage drug discovery platform story rather than a company with marketed products. Its value proposition depends on the scientific performance of IMP3ACT, the quality of its peptide conjugate pipeline, and its ability to move candidates from pre-clinical research into human studies while managing the capital demands typical of biotechnology development.